D

LB Pharmaceuticals Inc LBRX

NASDAQ
Recommendation
Dividend Power Score
Day's Range
$38.49$40.38
Latest Close
Volume
--
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
Corporate Info
Phone Number
212 605 0300
Address
One Pennsylvania Plaza
Suite 1025
New York, NY 10119
Country
United States
Year Founded
2015
Details
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Employees
49
Business Description
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.